India SEBI Regulatory Enforcement Actions — October 23, 2026

Consolidated revenue from operations rose to ₹5,290 Lakhs from ₹4,712 Lakhs (about 12% YoY) in Q1 FY27, showing underlying top-line momentum in continuing businesses

Standalone revenue from operations fell to ₹29 Lakhs from ₹38 Lakhs YoY and standalone PBT of ₹20,530 Lakhs is 99%+ a one-time ₹21,428 Lakhs investment gain, so headline profit should not be capitalised

Consolidated continuing operations deteriorated to a ₹661 Lakhs loss from ₹411 Lakhs a year earlier (about 61% wider), with reported PAT of ₹20,332 Lakhs entirely attributable to the SASPL divestment gain

SEBI QJA restraint on promoter directors dealing in securities for two years is stayed by SAT (7 May 2026), reducing near-term enforcement overhang but leaving the matter open until the November 2026 hearing

Qualified review conclusion under Regulation 33(3)(h) because coverage of assets fell below 80%, reducing confidence in the reported consolidated numbers until unreviewed subsidiaries are covered

Dr. Smiths Biotech (negative net worth of ₹(987.00) lakh) ceased to be a subsidiary on 23 October 2026, removing a loss-making entity that contributed only ₹1.03 lakh of ₹2,946.87 lakh total income, a clean-up event

Entire equity of Dr. Smiths was extinguished with no consideration receivable, and the disposal reduced consolidated net worth by 115.63% from ₹853.60 lakh, a material write-off to the balance sheet

Lava Cast Private Limited going-concern uncertainty flagged by auditors, a subsidiary-level solvency warning that could require further write-downs

SEBI QJA order restrains promoter directors from dealing in securities for two years (dated 5 Feb 2026); stay by SAT on 7 May 2026 is interim and the matter remains live until the November 2026 hearing

Auditors issued a qualified review conclusion because two subsidiaries and two step-down subsidiaries (revenue ₹3,411 Lakhs, PAT ₹547 Lakhs, assets ₹11,987 Lakhs) were unreviewed, breaching the 80% asset-coverage threshold under Regulation 33(3)(h)

Reported PAT of ₹20,332 Lakhs is driven by discontinued operations while continuing operations loss widened to ₹661 Lakhs from ₹411 Lakhs YoY, so the headline profit is non-recurring

Subsidiary Lava Cast Private Limited carries a going-concern uncertainty noted by auditors, exposing the group to potential impairment or deconsolidation

Standalone revenue from operations declined to ₹29 Lakhs from ₹38 Lakhs YoY (about -24%), indicating the parent is effectively a holding vehicle with minimal operating income

Deconsolidation of Dr. Smiths reduced consolidated net worth by 115.63% (from ₹853.60 lakh), signalling that the group's residual equity base is now materially smaller

Insolvency was initiated by SIDBI under Section 7 of the IBC and admitted by NCLT on 28 April 2025, indicating a lender-driven default history that warrants scrutiny of the parent's remaining credit exposures

SAT stay on the SEBI QJA restraint order gives the company a window to resolve the promoter-dealing matter before the November 2026 hearing; a favourable outcome would remove a governance overhang

Consolidated revenue growth of about 12% YoY (₹4,712 Lakhs to ₹5,290 Lakhs) in continuing operations suggests the core business is expanding, and a clean-up of discontinued and unreviewed entities could sharpen the earnings base

The ₹21,428 Lakhs investment gain demonstrates that the company has realisable value in its investment portfolio, and the SASPL divestment proves a monetisation route for non-core holdings

Once the two unreviewed subsidiaries and step-down entities are brought within review scope and the 80% threshold is restored, the qualification should lift, which would be a re-rating catalyst for the stock

Removal of the negative-net-worth Dr. Smiths entity eliminates an ongoing drag on the group; the parent can now focus on the remaining healthcare operations with a cleaner subsidiary structure

The NCLT-approved resolution plan by Ananta Medicare with unanimous CoC approval (25 December 2025) shows a completed IBC process, a template for how distressed healthcare assets are resolved and potentially valued by strategic buyers

Setco Automotive's headline profit rests on a ₹21,428 Lakhs investment gain while continuing operations loss widened, a pattern where one-time disposals obscure deteriorating core earnings; investors should adjust for discontinued and non-recurring items when valuing small-cap holding structures [IMPLICATION: Screen for PAT driven by discontinued operations]

The qualified review conclusion at Setco, driven by unreviewed subsidiaries and step-down entities representing ₹11,987 Lakhs of assets, highlights a recurring risk in multi-tier group structures where reviewed coverage falls below the 80% threshold; compliance teams should monitor Regulation 33(3)(h) coverage quarterly [IMPLICATION: Governance-quality discount likely warranted]

Cian Healthcare's loss of Dr. Smiths through NCLT resolution and Setco's going-concern flag at Lava Cast both show subsidiary-level distress propagating into parent-level net worth and disclosure obligations; expect further write-downs where subsidiaries carry negative net worth [IMPLICATION: Watch consolidated net worth trajectories]

The SEBI restraint on promoter directors dealing in securities, now stayed at SAT, reflects continuing regulatory focus on promoter conduct in listed Indian small-caps; the outcome of the November 2026 hearing will set a reference point for similar cases [IMPLICATION: Track SAT rulings on QJA stays]

SEBI QJA promoter-dealing restraint stayed on 7 May 2026; next hearing November 2026. Watch for final order or further stay extension [Nov 2026]

Monitor whether the two unreviewed subsidiaries and two step-down subsidiaries are brought into review scope in the Q2 FY27 filing to clear the qualified conclusion

Track any impairment, capital infusion, or deconsolidation at Lava Cast Private Limited following the auditors' going-concern flag

Watch whether the continuing operations loss (₹661 Lakhs in Q1 FY27 vs ₹411 Lakhs in Q1 FY26) narrows in subsequent quarters or continues to widen

Monitor consolidated net worth of the remaining group after the 115.63% reduction and any further restructuring or capital raise

Track any SIDBI or other lender claims or related disclosures linked to the IBC process to confirm no contingent liabilities remain with the parent